LUND, Sweden and CARPI, Italy, December 4 /PRNewswire/ -- ADITUS Medical AB and IGEA s.r.l., the leading companies in the field of electroporation, today announced a long-term agreement for the development and exploitation of intelligent Electro Chemo Therapy, “ECT”.
ECT is a method which fights cutaneous and sub-cuteaneous cancer by increasing the effect of certain chemotherapeutic drugs. With this method, the cancer patients now have a highly viable alternative to traditional radiation therapy and/or surgery.
The agreement will form an alliance within the electroporation area concerning research and development as well as sales and marketing. The goal of the alliance is - through synergies in technical achievements - to strengthen the position of ADITUS Medical and IGEA as the European leaders within cancer and gene therapy by means of electroporation.
Both companies have long experience in the field of electroporation. IGEA has developed an electroporation device, “Cliniporator” intended for clinical treatment within ECT. For the Electro Gene Therapy market (EGT), ADITUS has developed the equipment “CythorLab”. “CythorLab” has several technical benefits, making it ideal also within the research- and laboratory market as well as the ECT market.
Founded in 1997, ADITUS Medical is a pioneer in the field of Intelligent Electroporation and a leading provider of flexible, easy-to-use and powerful Electroporation devices for research and laboratory use in vivo & in vitro. Based on its patented technology for Impedance Controlled Electroporation, ADITUS develops unique devices using the impedance measurement as a feedback for optimum setup and control of the Electroporation process.
IGEA is a leading provider of intelligent solutions for oncology, orthopedics and diagnostics. It was founded in 1980 as a spin-off from the University of Modena by R. Cadossi MD researcher of the Dept. of Medical Oncological Radiological Sciences. The company is organized to carry-out all phases of the product in-house - from the initial idea to prototyping, manufacturing, marketing and sales. Headquartered in Carpi, Italy it has been a key member of the Cliniporator and ESOPE project which were funded by the European Union and resulted in the release of the CE certified Cliniporator, ready for clinical routine use.
For more information please visit http://www.aditusmedical.com or http://www.igea.it
ADITUS Medical AB
CONTACT: Contact: Anders Johnsson, E-mail:anders.johnsson@aditusmedical.se, Phone: +46-46-540-6215
